UK MHRA's Rawlins calls for new approach for clinical trials
This article was originally published in SRA
Executive Summary
New methods of analysis and novel clinical design are needed to achieve innovative drug development at lower costs to allow products to be sold at more affordable prices, according to Professor Sir Michael Rawlins, the recently appointed chairman of the UK’s Medicines and Healthcare products Regulatory Agency.